Opus Genetics, Inc. (IRD)
4.605
+0.16
(+3.48%)
USD |
NASDAQ |
Sep 03, 16:00
4.65
+0.04
(+0.98%)
After-Hours: 18:24
Opus Genetics Enterprise Value : 315.18M for Sept. 2, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 02, 2026 | 315.18M |
| September 01, 2026 | 263.93M |
| August 31, 2026 | 246.58M |
| August 28, 2026 | 252.36M |
| August 27, 2026 | 265.59M |
| August 26, 2026 | 261.45M |
| August 25, 2026 | 287.07M |
| August 24, 2026 | 280.46M |
| August 21, 2026 | 282.12M |
| August 20, 2026 | 287.90M |
| August 19, 2026 | 283.77M |
| August 18, 2026 | 252.36M |
| August 17, 2026 | 249.06M |
| August 14, 2026 | 245.75M |
| August 13, 2026 | 254.84M |
| August 12, 2026 | 258.15M |
| August 11, 2026 | 268.07M |
| August 10, 2026 | 249.88M |
| August 07, 2026 | 249.88M |
| August 06, 2026 | 254.84M |
| August 05, 2026 | 259.80M |
| August 04, 2026 | 254.02M |
| August 03, 2026 | 248.23M |
| July 31, 2026 | 254.02M |
| July 30, 2026 | 264.76M |
| Date | Value |
|---|---|
| July 29, 2026 | 234.18M |
| July 28, 2026 | 229.22M |
| July 27, 2026 | 224.26M |
| July 24, 2026 | 201.95M |
| July 23, 2026 | 188.72M |
| July 22, 2026 | 199.47M |
| July 21, 2026 | 200.29M |
| July 20, 2026 | 199.47M |
| July 17, 2026 | 217.65M |
| July 16, 2026 | 218.48M |
| July 15, 2026 | 235.01M |
| July 14, 2026 | 241.62M |
| July 13, 2026 | 262.28M |
| July 10, 2026 | 271.37M |
| July 09, 2026 | 279.64M |
| July 08, 2026 | 286.25M |
| July 07, 2026 | 282.12M |
| July 06, 2026 | 283.77M |
| July 02, 2026 | 296.99M |
| July 01, 2026 | 292.86M |
| June 30, 2026 | 287.07M |
| June 29, 2026 | 255.87M |
| June 26, 2026 | 251.58M |
| June 25, 2026 | 231.59M |
| June 24, 2026 | 230.88M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Perspective Therapeutics, Inc. | 120.75M |
| Praxis Precision Medicines, Inc. | 9.223B |
| Faeth Therapeutics, Inc. | 831.50M |
| Jade Biosciences, Inc. | 899.53M |
| ACADIA Pharmaceuticals, Inc. | 4.097B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.098M |
| Revenue (Quarterly) | 0.755M |
| Total Expenses (Quarterly) | 8.853M |
| EPS Diluted (Quarterly) | -0.139 |
| Gross Profit Margin (Quarterly) | 98.15% |
| Profit Margin (Quarterly) | -1.07K% |
| Earnings Yield | -29.90% |
| Normalized Earnings Yield | -18.60 |